



## ASX Company Announcement

### Madrid Convention Trademark Applications

19 March 2014

---

The Board of Sun Biomedical (ASX: SBN) is pleased to advise that commercialisation of the Oraline® family of saliva drug testing products continues to progress according to plan and the Company is extending its trademark protection in a number of markets under the WIPO Madrid System.

The Company has applied to extend its trademark for Oraline® in the following countries following the Madrid Protocol on the back of its US registration, currently in force until 2023.

- Australia
- Belarus
- China
- Czech Republic
- Germany
- European Union (Other countries)
- France
- United Kingdom
- Ireland
- Japan
- Latvia
- Mexico
- New Zealand
- Poland
- Russian Federation
- Singapore

This follows recent new applications made in the following non Madrid Convention countries.

- Canada
- Malaysia
- Indonesia
- Thailand.

These countries have been chosen for a number of reasons varying from the growing corporate user base (for example mining and oil and gas companies in Australia, Canada and the USA), through to the drug enforcement climate in particular countries.

“The timing for the reintroduction of Oraline® hand held drug testing units coincides with a growing awareness of saliva testing for its non invasiveness, convenience and compatibility with the demands and rights of people being tested”, said Howard Digby, Executive Chairman of Sun Biomedical Limited. “By combining one step convenience, user friendly design and quick and effective results, Oraline® offers users a welcome alternative to multi step, multi component testing systems.”

**About Sun Biomedical:**

Sun Biomedical Limited is an international biotechnology company with assets in the area of occupational drug testing. The Company is commercialising new improved versions of its “Oraline®” hand held multi drug test device while also looking to increase its biotechnology investments.

For more information about Sun Biomedical visit its corporate website at [www.sunbiomed.com.au](http://www.sunbiomed.com.au)

Howard Digby  
Executive Chairman  
+61 434 987 750